Article

FDA Approves New Drug Combination to Treat Endometrial Cancer

The combination use of Keytruda and Lenvima is now approved to treat a subset of patients with advanced endometrial cancer.

The Food and Drug Administration (FDA) has approved a combination of two drugs — Lenvima (lenvatinib) and Keytruda (pembrolizumab) – to treat a subset of patients with advanced endometrial carcinoma.

The targeted drug and immunotherapy received accelerated approval as a treatment for patients whose endometrial cancer is not categorized as microsatellite instability-high or mismatch repair deficient, who are not eligible for curative surgery or radiation, and whose disease has progressed after previous systemic therapy. The approval was based on a study of 94 patients, a little over one-third of whom had a response to the regimen that lasted up to six months.

The decision was made under a new initiative of the FDA Oncology Center of Excellence, known as Project Orbis, which is designed to allow international partners to concurrently submit oncology drugs for review. In addition to the FDA, the Australian Therapeutic Goods Administration and Health Canada collaborated on the review of the combination, leading to simultaneous approvals in all three countries.

“We are pleased to be working alongside our Australian and Canadian colleagues to help make potentially life-changing treatments available to patients as quickly as possible while still ensuring the FDA’s high standards of safety and effectiveness,” acting FDA commissioner, Dr. Ned Sharpless, stated in the press release. “As Project Orbis expands, we look forward to welcoming additional international partners to collaborate with us in this important initiative as we work to help further serve the global patient community.”

Check back later to learn more about how this approval will affect patients with advanced endometrial cancer.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Daniel Jernazian, who beat cancer twice, credits his sports mindset for survival and calls it winning his ‘life World Championship’.
Patients in rural or underserved areas may have worse outcomes, highlighting the need for early support to address care access barriers.
Image of man with text.
Image of doctor with text.
Dr. Emre Yekedüz discusses how ASCO 2025 highlights precision medicine, biomarkers and the gut microbiome as keys to advancing kidney cancer care.
Dr. Breelyn Wilky stresses the importance of expert guidance and second opinions for patients with GIST, as treatment options continue to evolve rapidly.
Mark Daniels, 83, credits CAR T-cell therapy and compassionate care for helping him overcome lymphoma and endure the isolating treatment toll.
An early study of BGB-16673 for hard-to-treat leukemia found that side effects were manageable with no new safety concerns.
Image of woman with text.
Image of goy, and text.
Related Content